Advertisement


Martin Reck, MD, PhD, on Immunotherapy for Thoracic Malignancies: Expert Perspective

ESMO 2018 Congress

Advertisement

Martin Reck, MD, PhD, of the LungenClinic, discusses recent updates on biomarkers beyond PD-L1 expression; mechanisms and management of resistance; as well as combinations and novel approaches in lung cancer.



Related Videos

Geriatric Oncology
Immunotherapy

Matti S. Aapro, MD, on Immunotherapy in Older Patients

Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the optimal treatment and supportive care for older patients with cancer, including the importance of maintaining dose density and intensity as well as monitoring toxicity.

Bladder Cancer
Immunotherapy

Ronald de Wit, MD, PhD, on Bladder Cancer: Results From KEYNOTE-057

Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses phase II findings on the efficacy of pembrolizumab in bacillus Calmette-Guérin–unresponsive bladder cancer with high risk for disease progression.

Skin Cancer

Alexander M.M. Eggermont, MD, PhD, on Melanoma: Advances in Adjuvant Therapy

Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanoma, and what the NCCN Guidelines recommend in light of such data as results on dabrafenib plus trametinib vs anti–PD-1 treatments (nivolumab or pembrolizumab) and the new standard for wild-type disease.

Lung Cancer
Immunotherapy

Tony Mok, MD, on NSCLC: Targeted Treatment Update

Tony Mok, MD, of the Chinese University of Hong Kong, discusses two important studies in non–small cell lung cancer: FLAURA, which looked at the first-line activity of osimertinib and the mechanisms of resistance; and ALESIA, which examined crizotinib dosing.  

Prostate Cancer

Nicholas D. James, PhD, MBBS, on Prostate Cancer: Updates From the STAMPEDE Trial

Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses study findings on treating metastatic castration-sensitive prostate cancer, including results on radiotherapy and abiraterone (Abstract LBA5_PR).

Advertisement

Advertisement




Advertisement